All Trials

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant, RECIST-measurable high-grade serous ovarian/fallopian tube/primary peritoneal cancer with CCNE1 (Cyclin E1) overexpression after 1–4 prior systemic lines (with prior bevacizumab and, if FRα-positive, prior mirvetuximab expected) are randomized to INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E1–driven cell-cycle progression, versus investigator’s choice standard single-agent chemotherapy.

ClinicalTrials.gov ID: NCT07214779

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent platinum-sensitive high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal cancer who have completed second-line platinum doublet chemotherapy and have CR/NED, PR, or stable disease (and BRCA-mut/HRD+ patients must have previously received 1L PARP maintenance) are randomized within 8 weeks to maintenance rinatabart sesutecan plus standard-of-care (bevacizumab maintenance if chosen or observation) versus standard-of-care alone. Rinatabart sesutecan is an FRα-targeted antibody–drug conjugate that delivers an intracellular topoisomerase I inhibitor payload to FRα-expressing tumor cells.

ClinicalTrials.gov ID: NCT07225270

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with unresectable locally advanced or metastatic primary bone sarcomas—osteosarcoma, Ewing sarcoma, grade 2–3 conventional chondrosarcoma with RECIST progression within 12 weeks, or other rare bone sarcomas—who are relapsed/refractory after ≥1 prior systemic therapy (≤2 prior lines in advanced/metastatic setting), ECOG 0–2, measurable disease, and no prior VEGF-targeted TKI. Treatment is oral once-daily zanzalintinib monotherapy, an investigational multi-target TKI inhibiting VEGFR2, MET, and TAM kinases (AXL/MER/TYRO3), continued until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07193550

Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with previously untreated extensive-stage small cell lung cancer, measurable disease (RECIST v1.1), ECOG 0–1, and adequate organ function, excluding symptomatic/high-risk CNS metastases and patients with significant bleeding/vascular risk or active autoimmune disease requiring systemic therapy. Patients are randomized to carboplatin/etoposide plus ivonescimab 10 mg/kg vs 20 mg/kg for 4 induction cycles, then ivonescimab maintenance; ivonescimab is a tetravalent bispecific antibody targeting PD-1 and VEGF (checkpoint blockade plus anti-angiogenic activity).

ClinicalTrials.gov ID: NCT07057791

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with histologically/cytologically confirmed SCLC who progressed during/after one prior platinum-based regimen (prior 2L tarlatamab allowed), with RECIST-measurable disease, ECOG 0–1, and allowing treated/stable or asymptomatic CNS metastases. Patients are randomized to ZL-1310, a DLL3-targeted antibody–drug conjugate delivering a camptothecin-derived topoisomerase I inhibitor payload, versus investigator’s choice standard therapy.

ClinicalTrials.gov ID: NCT07218146

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adult women with measurable recurrent endometrial cancer (including uterine carcinosarcoma) with central HER2 IHC 1+/2+ after ≥1 platinum regimen and prior anti–PD-1/PD-L1 (randomized 2:1) or HER2 IHC 3+ (single-arm), ECOG 0–2, and no prior topoisomerase I inhibitor/ADC exposure or significant ILD/pneumonitis. Treatment is the HER2-targeted antibody–drug conjugate BNT323/DB-1303 (anti-HER2 IgG1 linked to a cleavable topoisomerase I inhibitor payload) versus investigator’s choice single-agent chemotherapy (preferably doxorubicin or paclitaxel; docetaxel allowed).

ClinicalTrials.gov ID: NCT06340568

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized trial for adults with ECOG 0–1 locally advanced/metastatic urothelial carcinoma with progression after prior platinum chemotherapy, anti–PD-1/PD-L1 therapy, and enfortumab vedotin, with no prior TROP2-directed or topoisomerase I ADC exposure. Participants receive sacituzumab tirumotecan, a TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload, versus investigator’s choice of paclitaxel, docetaxel, or vinflunine.

ClinicalTrials.gov ID: NCT07419295

A Single-Arm, Phase II Study of Ivonescimab in Combination With FOLFOX in Advanced HER2 Negative Gastroesophageal Adenocarcinomas

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated locally advanced unresectable or metastatic HER2-negative adenocarcinoma of the esophagus, GEJ, or stomach receive first-line ivonescimab plus FOLFOX. Ivonescimab is an investigational tetravalent bispecific antibody that blocks both PD-1 and VEGF, combining checkpoint inhibition with anti-angiogenic activity.

ClinicalTrials.gov ID: NCT07070466

Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized first-line study for adults with PD-L1 CPS ≥1 recurrent/metastatic HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx, with measurable disease and ECOG 0–1, no prior systemic therapy for R/M disease, and stratified by HPV status. Patients receive fianlimab, an anti–LAG-3 immune checkpoint antibody, plus cemiplimab anti–PD-1 versus cemiplimab plus placebo.

ClinicalTrials.gov ID: NCT06769698

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with ECOG 0–1 metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab, with no more than 2 prior metastatic regimens, are randomized to later-line therapy. The study compares precemtabart tocentecan, a CEACAM5-directed antibody–drug conjugate with an exatecan topoisomerase I inhibitor payload, with or without bevacizumab versus trifluridine/tipiracil plus bevacizumab.

ClinicalTrials.gov ID: NCT07549412